MedTrace Logo

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

NCT07390123 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 370

Last updated 2026-02-05

No results posted yet for this study

Summary

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

Conditions

  • IgA Nephropathy (IgAN)

Interventions

DRUG

HSK39297

HSK39297 200mg, once a day; treatment period; 48-weeks fixed dose.

DRUG

Placebo

Placebo, once a day; treatment period; 48-weeks fixed dose.

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2027-12-31
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07390123 on ClinicalTrials.gov